- Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
Watch Geron's latest callGeron (NASDAQ:GERN) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Geron (NASDAQ:GERN) Q2 2026 Earnings CallGeron's next earnings callGeron (NASDAQ:GERN) Q3 2026 Earnings Call · Nov 4, 2026 at 8:00 AM ESTRegister
Story so far
- Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
- Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
- Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
Earlier from Geron
- Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
- Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
- Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
- Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
- Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
Later from Geron
- Geron to Host Virtual Investor Event on June 14, 2023
- Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
- Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
- Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
- Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
Follow Geron into a list and get an email when it puts out news.
Follow Geron